Belantamab ELISA Kit

• Background:

  Belantamab mafodotin also known as GSK2857916 is a humanized, IgG1 antibody-drug conjugate (ADC) that binds specifically to BCMA. The parent anti-BCMA antibody (GSK2857914) is produced in an afucosylated form and is conjugated to the microtubule polymerization inhibitor MMAF, via a protease-resistant maleimidocaproyl (mc) linker, to produce the GSK2857916 ADC molecule. Upon binding to the cell surface, GSK2857916 is rapidly internalized and active cytotoxic drug (cys-mcMMAF) is released inside the cell causing cell-cycle arrest and apoptosis. Furthermore, the afucosylation of GSK2857916 leads to enhanced binding to FcγRIIIa receptors on the surface of immune effector cells, recruitment of immune cells, and antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP, respectively) . This dual mechanism of action enables improved efficacy by targeting both dividing (via ADC) and non-dividing (via ADCC/ADCP) tumor cells. Recently, belantamab mafodotin was approved under the name BLENREP in the United States and European Union for the treatment of patients with relapsed or refractory multiple myeloma.

• Specifications:

  Belantamab

• Product Name Alternative:

  2857916, GSK2857916, J6M0, J6M0-mcMMAF, CAS: 2061894-48-0

• Detection Method:

  Colorimetric

• Assay Type:

  Quantitative

• Sample Type:

  Plasma, Serum

• Detection Range:

  0.31-5 μg/mL

• Recovery:

  80-120%

• Sensitivity:

  0.156 μg/ml

• Shipping Conditions:

  2-8 °C

• Storage Conditions:

  The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

• Notes:

  For Research Use Only.